In first instance, we found slightly significant differences in AURKA expression in the MNC fraction from CML patient who responded to TK inhibitors compared to a pool of peripheral blood apheresis from healthy donors (p < 005). The gene discussed is TKT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.